benefits of microdosing glp-1 Agonists: Using Semaglutide, Tirzepatide, and Orforglipron for Weight Loss and Obesity Why GLP-1 Microdosing? A Closer

Newer agents appear to be more effective at A1c and weight lowering, and its a very exciting time for the treatment of type 2 diabetes and obesity when the new GLP-1 agonists are able to achieve more robust A1c lowering than any other existing diabetes medication other than insulin, she told Healthline

What the FDA proposed on April 30, 2026 directly affects the availability and legal status of compounded semaglutide and tirzepatide

Connect with a prescriber here

Drug interactions: Orforglipron's CYP3A-mediated metabolism raises the potential for drug-drug interactions with strong CYP3A inhibitors and inducers

And it might be the most important one in this entire guide